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The 2003 International Society of Nephrology (ISN)/Renal
Pathology Society (RPS) Classification of lupus nephritis (LN)
was designed to eliminate ambiguities and standardize
definitions. Major changes from the 1982 Modified WHO
Classification include the elimination of the normal biopsy
category and the subcategories of membranous Class V, the
introduction of sharper distinctions between the classes, and
the addition of subcategories within diffuse LN (class IV) for
predominantly segmental (LN IV-S) and global (LN IV-G)
lesions. It stipulates that sclerotic glomeruli owing to scarred
LN should be taken into account when assessing the
percentage of glomeruli affected by LN. Since its publication,
the ISN/RPS classification has been used successfully in a
number of clinical-pathologic studies. Several studies
addressing the relationship between LN IV-S and LN IV-G
have failed to identify a significantly worse outcome in IV-S
than IV-G, although there were some differences in
presenting clinical and pathologic features. Importantly, the
ISN/RPS classification has achieved its goal of improved
interobserver reproducibility. Its use has increased the
percentage of LN biopsies meeting criteria for class IV. As it
gains widespread acceptance, the ISN/RPS classification is
already providing a standardized approach to renal biopsy
interpretation needed to compare outcome data across
centers.
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In May of 2002, an international group of 23 individuals
including pathologists, nephrologists, and rheumatologists
convened at Columbia University in New York, New York to
develop a revised classification of lupus nephritis (LN).
Working under the auspices of the International Society of
Nephrology (ISN) and the Renal Pathology Society (RPS),
the group aimed to ‘accommodate the clinicopathologic and
pathogenetic insights that have accumulated since the 1982
and 1995 modifications of the original 1974 WHO
classification and to eliminate inconsistencies and ambi-
guities’. The meeting was spurred by a widely perceived need
to re-examine existing classifications, provide clearer defini-
tions and distinctions between the classes, and improve
reproducibility and interobserver agreement. As a testament
to the importance of this document in the international renal
community, the ISN/RPS 2003 classification of LN was
published simultaneously in Kidney International and the
Journal of the American Society of Nephrology in February
20041,2 (Table 1).
ISN/RPS 2003 CLASSIFICATION OF LN: SUMMARY OF
CHANGES
The group set out to use definitions that would be workable
wherever renal pathology is practiced in the world. Because
many centers outside the US routinely use light microscopy
(LM) and immunofluorescence (IF), but may not have access
to electron microscopy, the definitions chosen reflect that
bias. The working group was unanimous in its decision to
eliminate a ‘normal’ renal biopsy from the classification of
LN, both because this situation is rare in clinical practice and
because it is a fundamental contradiction in terms to refer to
a normal biopsy as a manifestation of disease. Instead, it
substituted the mildest possible form of LN for class I.
Termed ‘minimal mesangial LN’, class I is defined as normal
appearing glomeruli by LM with immune deposits confined
to the mesangium by IF. Class II, ‘mesangial LN’, is defined by
mesangial proliferation by LM and mesangial deposits by IF.
Because no studies have shown a difference in prognosis
between cases with mild, moderate, or severe mesangial
proliferation, class II includes mesangial proliferation of any
degree. Class II allows for the existence of a rare minute
subendothelial or subepithelial deposit visible by IF or
electron microscopy, but not by LM. This accommodation
was made because of the general experience among renal
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pathologists that this situation is not unusual and should not
be overinterpreted as a higher lesion. On the other hand,
subendothelial deposits that are visible by LM without
endocapillary proliferation are incompatible with class II and
should be diagnosed as class III or IV depending on their
distribution in 4 or o50% of glomeruli. A subtle but
important change in the ISN/RPS classification is to
substitute the term ‘focal LN’ for ‘focal proliferative LN’;
similarly ‘diffuse LN’ replaces ‘diffuse proliferative LN’. This
refinement was introduced to reflect the heterogeneous
phenotype of the class III and IV lesions, which do not
always manifest classical endocapillary proliferation. It allows
for a variety of endocapillary and extracapillary changes,
including membranoproliferative features without luminal
closure, subendothelial deposits visible by LM without
endocapillary proliferation, and crescents without endoca-
pillary proliferation. The distinction between class III and IV
is defined precisely as o50% of glomeruli exhibiting such
endocapillary or extracapillary lesions in class III and X50%
in class IV. For class III, the focal lesions may be segmental or
global. For class IV, subcategories were added depending on
whether the majority (X50%) of lesions were segmental
(designated as IV-S) or global (designated as IV-G) (Figure 1).
Instead of using numbered or lettered subcategories for active
and chronic lesions, the ISN/RPS classification affixes a
simple mnemonic (A) for purely active lesions, (C) for purely
chronic lesions, and (A/C) for any combination of active and
chronic lesions.3,4
In the 1982 WHO classification of LN, class V (membra-
nous LN) contained subcategories to describe the overlap of
class V with Class II (Vb), III (Vc), or IV (Vd). This placed
undue emphasis on the membranous lesion at the expense of
the more dangerous proliferative lesion, creating the
potential for serious miscommunications.3 In the ISN/RPS
classification, these subcategories have been eliminated such
that a biopsy with features of both diffuse LN and
membranous LN is accorded separate diagnoses of class IV
and class V in the diagnostic line. For the first time a
threshold for the diagnosis of membranous LN (class V) in
the setting of focal or diffuse LN has been defined. An
additional diagnosis of membranous LN class V is made
when subepithelial deposits involveX50% of the glomerular
tuft in X50% of glomeruli. This simple rule of X50%
(indicating involvement of the majority of glomeruli) is a
recurring motif throughout the ISN/RPS classification that is
both logical and easy to remember. Finally, LN class VI
(‘advanced sclerosing LN’) is now more clearly defined,
requiring that 490% of glomeruli be globally sclerotic with
no evidence of ongoing activity.
The ISN/RPS classification sets down a simple, but
important, stipulation that may seem obvious. It requires
that the diagnostic line of the report include entries for the
attendant tubulointerstitial and vascular lesions. Tubular
atrophy, interstitial fibrosis, inflammation, and forms of
arteriopathy should be separately enumerated and graded.
Because the classification covers only immune complex-
mediated forms of glomerulonephritis, separate diagnoses
should be entered for other pathologic processes, such as
thrombotic microangiopathy or forms of podocytopathy
Table 1 | ISN/RPS (2003) classification of LN
Class I Minimal mesangial LN
Class II Mesangial proliferative LN
Class III Focal LN* (o50% of glomeruli)
III (A): active lesions
III (A/C): active and chronic lesions
III (C): chronic lesions
Class IV Diffuse LN* (X50% of glomeruli)
Diffuse segmental (IV-S) or global (IV-G) LN
IV (A): active lesions
IV (A/C): active and chronic lesions
IV (C): chronic lesions
Class V Membranous LN
Class VI Advanced sclerosing LN
(X90% globally sclerosed glomeruli without residual activity)
LN, lupus nephritis.
*Indicate the proportion of glomeruli with active and with sclerotic lesions.
*Indicate the proportion of glomeruli with fibrinoid necrosis and with cellular
crescents.
*Indicate and grade (mild, moderate, and severe) tubular atrophy, interstitial
inflammation and fibrosis, severity of arteriosclerosis, or other vascular lesions.
*Class V may occur in combination with III or IV in which case both will be
diagnosed.
a b
Figure 1 | Diffuse LN (class IV). (a) Low power views showing diffuse segmental and (b) diffuse global endocapillary proliferative
glomerulonephritis, typical of LN class IV-S and IV-G, respectively. (a) Jones methenamine silver at original magnification  100 and
(b) hematoxylin and eosin at original magnification  100.
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(such as minimal change disease or collapsing focal
segmental glomerulosclerosis).5,6 Although self-evident, the
importance of these practical guidelines to biopsy reporting
cannot be underestimated.
LN CLASS IV-S VS IV-G: ‘TO BE OR NOT TO BE’
Undoubtedly the most controversial aspect of the ISN/RPS
2003 classification is the introduction of a subclassification
within diffuse LN (class IV) for biopsies with predominantly
segmental (‘IV-S’) or global (‘IV-G’) distribution of lesions.
Although intuitively one might think that global endocapil-
lary lesions (IV-G) carry a worse prognosis, this is not
necessarily so.7 The Lupus Nephritis Collaborative Study
Group performed a prospective study on ‘severe LN’ that
included 24 patients who met modern criteria for LN IV-S
and 35 patients who met criteria for LN IV-G.7 Both groups
were similar with respect to baseline clinical and serologic
parameters. On renal biopsy, LN IV-S had more segmental
endocapillary proliferation and fibrinoid necrosis. In con-
trast, LN IV-G was more commonly associated with large
subendothelial ‘wire loop’ deposits and intracapillary depos-
its (‘hyaline thrombi’), suggesting higher immune complex
load. Patients with LN IV-S had lower activity and higher
chronicity indices, although the differences did not reach
statistical significance. The two groups received similar
treatment including prednisone, cyclophosphamide, and in
some cases plasmapheresis. The 5-year cumulative remission
rate was 73% for patients with LN IV-G vs 48% for LN IV-S
(Po0.05). Renal survival at 10 years was 75% for LN IV-G vs
52% for LN IV-S (Po0.05). The authors concluded that
biopsies with segmental endocapillary proliferation involving
450% of glomeruli (which they had called ‘class III450%’,
now termed IV-S) should be included within class IV, appear
to have a worse prognosis than biopsies with diffuse
endocapillary proliferation (LN IV-G), and may require
more aggressive therapy. The authors speculated that
different pathogenetic mechanisms may be operant in this
group, which exhibits significantly less immune complex
deposition than IV-G, resembling a ‘pauci-immune’ GN.
Potential roles for anti-neutrophil antibody, anti-endothelial
antibody, and anticardiolipin antibody have been proposed,
but none of these have been studied systematically. This study
suggested that these subgroups are qualitatively different,
such that LN IV-S and LN IV-G do not represent a simple
continuum of disease.7 The distinction between LN IV-S and
IV-G was incorporated in the ISN/RPS 2003 classification to
allow multiple centers in different parts of the world to
examine this issue.
SCLEROTIC GLOMERULI: STAND UP AND BE COUNTED
Another major emphasis in the ISN/RPS 2003 classification
of LN is the handling of sclerotic glomeruli. The previous
classification systems for LN did not specifically address
this issue, leading to major differences in practice among
renal pathologists. Some renal pathologists would ignore
sclerotic glomeruli when determining the percentage of
glomeruli affected by LN whereas others factored both
scarred and nonsclerotic glomeruli into the equation.
According to the ISN/RPS system, both active and chronic
scarred glomeruli must be taken into account. Thus, ‘global
or segmental glomerular scars that are interpreted as the
chronic sequela of previous glomerular endocapillary pro-
liferation, necrosis, or crescents must be considered mani-
festations of focal or diffuse LN and should be included in a
count of total glomeruli affected. Wherever possible, how-
ever, glomeruli with ischemic obsolescence (as frequently
observed in the subcapsular cortex) should be excluded. The
classification also allows for class V to develop lesions of
segmental or global sclerosis as it evolves to chronicity,
without necessarily implying transformation to a prolifera-
tive class. Thus not all sclerosing lesions carry the same
implications and the pathologist should use whatever clues
are available to determine by what route a glomerulus
may have become sclerotic. Understandably, this may not
always be possible without vision of hindsight. If renal
pathologists assume that any globally sclerotic glomeruli
found in a biopsy from a young adult with systemic lupus
erythematosus is the sequela of a previous proliferative
lesion, the number of biopsies diagnosed as class III or IV will
necessarily increase.8
ACTIVITY AND CHRONICITY: DO WE NEED AN INDEX?
In the ISN/RPS 2003 classification of LN, the renal
pathologist should indicate the proportion of glomeruli with
active and chronic lesions in the diagnostic line of the biopsy
report. In particular the proportion of glomeruli with
fibrinoid necrosis and cellular crescents should be specified.
In this way, important information about activity and
chronicity is recorded regardless of whether the pathologist
uses a formal activity and chronicity index. A list of which
lesions meet criteria for active and chronic lesions was clearly
set forth by the working group.1,2 Pathologists are encour-
aged, but not required, to supplement their reports with an
activity or chronicity index, such as the National Institute of
Health scoring system or another index of their choice.9 At
Columbia University, we have used the National Institute of
Health scoring system for 2 decades; we have found that this
information is useful to our clinicians and its inclusion is
generally appreciated, particularly when comparing changes
over time in repeat biopsies from individual patients. Of
course, more important than the actual numerical score for
total activity and chronicity is the microscopic description of
the various components of activity and chronicity, because
the presence of such active features as subendothelial deposits
or interstitial inflammation are generally regarded as more
reversible with therapy than such ominous lesions as cellular
crescents or necrosis.
INITIAL OBSERVATIONS FROM THE LITERATURE: LN IV-S
VS IV-G
The distinction between LN class IV-S and IV-G has been the
subject of three recent retrospective studies.10–12 The three
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studies, performed on different continents, have failed to
show a worse outcome in LN IV-S vs IV-G, although there
were some clinical and morphologic differences.10–12 Mittal
et al.10 compared 11 patients who met criteria for LN IV-S
with 22 patients with LN IV-G. Patients with LN IV-G had
worse renal function and were more commonly hypertensive
at baseline. With the exception of the distribution of lesions,
both groups were similar with respect to other histologic
parameters, activity and chronicity indices, treatment, and
outcomes, leading the authors to conclude that the distinc-
tion between LN IV-S and IV-G ‘may not be justified’.10
Yokoyama et al.11 evaluated a smaller, Japanese cohort that
included 6 patients with LN IV-S and 17 with LN IV-G. The
two groups were similar with respect to baseline clinical
parameters. The mean renal survival was 95 months for LN
IV-S vs 214 months for LN IV-G, although this difference did
not reach statistical significance (P¼ 0.1495).11 The findings
in this study must be interpreted with caution because
individual patients were not treated uniformly and patients
with LN IV-S were less likely to have received aggressive
therapy.
The largest study on LN IV-S and LN IV-G compared
15 French patients with LN IV-S and 31 with LN IV-G
and found that at baseline, patients with LN IV-G had
more proteinuria, renal insufficiency, anemia, and hypocom-
plementemia.12 On pathologic evaluation, LN IV-G was
associated with more membranoproliferative features,
wire loop deposits and hyaline thrombi, greater IF positivity
involving the peripheral capillary walls, and less fibrinoid
necrosis. After initial biopsy, patients received steroids
with or without cyclophosphamide and underwent a
second protocol biopsy 6 months later. Clinical outcomes
at 10 years follow-up were similar for patients with LN IV-S
and LN IV-G diagnosed at the first renal biopsy. Over
the initial 6-month interval, 30 of the 46 patients
converted to mesangial proliferative LN (class II). Among
the remaining 16 patients, the second biopsy showed
transformation to IV-S in seven patients (all originally IV-
G) and nine cases of IV-G (three of which were transforma-
tions from IV-S). Those patients with a 6-month biopsy
diagnosis of LN IV-S had significantly better clinical outcome
than those with IV-G.12 The authors compared their findings
to the previous two studies on LN IV-S vs IV-G10–11 as well as
the study by the Lupus Nephritis Collaborative Study Group7
and concluded that while there are some clinical and
pathologic differences between IV-S and IV-G, outcomes
are similar.12
These studies have given us new insights into the IV-S/IV-
G paradigm. Two studies have shown interconversion
between IV-S and IV-G in repeat biopsies, arguing against
the concept of distinct pathomechanisms of disease.10,12 Thus
the hypothesis that IV-S may represent an early stage in the
evolution of class IV-G cannot be dismissed. Most of the
studies have drawn analogies between ‘pauci-immune’
anti-neutrophil cytoplasmic autoantibody-associated glomer-
ulonephritis and LN IV-S, which often has prominent
necrotizing features and minimal immune deposits.7,10,12
Anti-neutrophil cytoplasmic autoantibody seropositivity is
commonly encountered in patients with systemic lupus
erythematosus13 and cases have been described in which the
disproportionate necrotizing and crescentic features in a
patient with systemic lupus erythematosus led to the
discovery of a positive anti-neutrophil cytoplasmic autoanti-
body, suggesting that overlaps between these disease
processes can occur.14,15 Despite these observations, no study
has examined systematically the prevalence of anti-neutrophil
cytoplasmic autoantibody seropositivity in cases of LN IV-S.
Clearly, more studies addressing these differences are needed.
Whether a distinction between IV-S and IV-G will be retained
in future iterations of the classification should depend on
whether it proves to have important clinical or pathogenetic
implications.
INTEROBSERVER REPRODUCIBILITY
The success of a classification system is ultimately determined
by its reproducibility and clinical relevance. A large study
involving 20 centers in the UK recently found a significantly
higher interobserver reproducibility for the ISN/RPS (2003)
than the modified WHO (1982) classification.8 In this study,
renal pathologists classified cases of LN by the WHO system
and then were asked to reclassify the same cases by the ISN/
RPS 2003 classification 1 year later. The improved reprodu-
cibility of the ISN/RPS classification was ascribed to clearer
separations between the classes and the elimination of
subgroups of class V. The percentage of cases of class IV
increased from 23% by the WHO 1982 classification to 46%
by the ISN/RPS 2003 classification.8 The increase in biopsy
incidence of class IV could be attributed primarily to the
elimination of class Vd as a subgroup of membranous and
the inclusion of sclerotic glomeruli in the assessment of total
glomeruli affected. The authors concluded that the ISN/RPS
2003 classification has achieved its goal of improved
interobserver reproducibility, but warned that newer out-
come studies based on the modern classification cannot be
compared blindly to older studies employing earlier classi-
fications without keeping in mind the differences in
pathologic entry criteria. Another study has confirmed the
higher consensus in reporting among pathologists using the
2003 ISN/RPS than the 1982 WHO classification.11
ISN/RPS CLASSIFICATION OF LN: STRENGTHS AND
WEAKNESSES
What are the drawbacks of the new classification? There
remains some confusion about the importance of subendothe-
lial deposits in the diagnosis of class III and class IV. One of the
most frequently asked questions is how to handle a case in
which no subendothelial deposits or endocapillary lesions are
visible by LM, but substantial subendothelial deposits are
detected by IF or electron microscopy. In our view, such a case
should be classified as class III if the subendothelial deposits
involveo50% of glomeruli and class IV if they involveX50%
of glomeruli. A renal biopsy is always subject to sampling bias,
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and it is important for the same pathologist to interpret and
integrate the findings by all three modalities. This point may
not have been adequately stressed in the original classification
document. Implied by the ISN/RPS classification, but not
explicitly stated, is that substantial subendothelial deposits are
defining features of active class III and class IV, regardless of
the proliferative pattern.
Another frequently asked question is how much active and
chronic lesions are needed for the designations of ‘A’ and ‘C’.
According to the definitions proposed, a single glomerular
lesion with any feature of activity is enough to assign ‘A’ for
active. Similarly, a single segmentally or globally sclerotic
glomerulus judged to be sclerotic as a consequence of scarred
glomerulonephritis merits a designation of ‘C’. Obviously the
presence of high activity (vs low activity) is an important
issue when deciding whether to pursue aggressive therapy,
and there is no substitute for quantifying active and chronic
lesions in the body of the microscopic description and on the
diagnostic line.
Is the ISN/RPS classification of LN more clinically relevant
than its predecessors? There is no doubt that elimination of
the normal renal biopsy and the class Va-Vd subclasses are
improvements. The use of (A) and (C) designations for active
and chronic lesions has simplified reporting and given us a
universal language that is easy to remember whether we are
pathologists or clinicians. Clear definitions have allowed
complex issues, such as the distinction between class IV-S and
IV-G, to be rigorously tested at centers throughout the
world.10–12 Early indications that the ISN/RPS classification is
more reproducible among pathologists must be considered a
major achievement.
CONCLUSION
The ISN/RPS classification of LN represents a significant
advance over the 1982 WHO schema. It is logical, easy to use,
and highly reproducible. It has eliminated clinically irrelevant
and cumbersome subclasses. The ultimate measure of
acceptance of a new system is whether it is being used. A
recent informal poll of an international group of renal
pathologists at the International Academy of Pathology held
in Montreal in September 2006 indicated by a show of hands
that the vast majority of renal pathologists are using the new
classification in their daily practice and consider it an
improvement. Whether they follow the practice guidelines
strictly is another issue, and admittedly some individual
preferences prevail. The great strengths of the classification
are that it has not made any major departures from accepted
doctrines and that it is flexible enough to allow for future
modifications as newer clinical and pathogenetic insights
emerge. In the meantime it provides a valuable framework
for well-defined prospective studies on treatment and
prognosis. To what extent pathologic differences between
the classes reflect pathogenetic differences is a much more
difficult question that should pose the greater challenge for
investigators in the years to come.16
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